NTRK1

But there are other examples as well.

NTRK is another fusion protein that occurs that we've got a specific drug for.

The successes are discrete, but there are some and they've been really revolutionary.

And then lastly, although it's not exactly chemotherapy, but more like immunotherapy, is kind of one of the newer ways that we're attacking some of these tumors, which is really marshalling the immune system to recognize the tumor cells and to attack the tumor cells.

For all non-squamous, and you can consider for squamous, the panel should cover at least 80%.

EGFR, KRAS, ALK, ROS1, BRAF, NTRK, MET Exon 14, RET, HER2 mutations, NRG1 plus HER2 IHC, and CMET HGF receptor IHC along with the PD-L1.

EGFR, ALK, RET, PD-L1 carry Category 1 designations, and that list continues on.

CMET-IHC and HER2-IHC are now part of routine workup because there are drugs tied to these.

Yeah, and I think particular mutations that might drive change in management can be present in even greater than 5% of glioblastoma patients.

And even outside of clinical trials, a lot of people are using, you know, off-label usage of medications, whether it might be an NTRK inhibitor, maybe it's immunotherapy for someone with mismatch repair deficiency.

I mean, there's so many things that could come out of that sequencing that could really have a significant change in management.

And if 60% of the patients are being cared for in the community, that's a substantial number of total brain tumor patients in this country each year.